The ALPMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ALPMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ALPMY Detailed Price Forecast - CNN Money||View ALPMY Detailed Summary - Google Finance|
|View ALPMY Detailed Summary - Yahoo! Finance||View ALPMY Stock Research & Analysis - Zacks.com|
|View ALPMY Trends & Analysis - Trade-Ideas||View ALPMY Major Holders - Barrons|
|View ALPMY Call Transcripts - NASDAQ||View ALPMY Breaking News & Analysis - Seeking Alpha|
|View ALPMY Annual Report - CompanySpotlight.com||View ALPMY OTC Short Report - OTCShortReport.com|
|View ALPMY Fundamentals - TradeKing||View ALPMY SEC Filings - Bar Chart|
|View Historical Prices for ALPMY - The WSJ||View Performance/Total Return for ALPMY - Morningstar|
|View the Analyst Estimates for ALPMY - MarketWatch||View the Earnings History for ALPMY - CNBC|
|View the ALPMY Earnings - StockMarketWatch||View ALPMY Buy or Sell Recommendations - MacroAxis|
|View the ALPMY Bullish Patterns - American Bulls||View ALPMY Short Pain Metrics - ShortPainBot.com|
|View ALPMY Stock Mentions - StockTwits||View ALPMY Stock Mentions - PennyStockTweets|
|View ALPMY Stock Mentions - Twitter||View ALPMY Investment Forum News - Investor Hub|
|View ALPMY Stock Mentions - Yahoo! Message Board||View ALPMY Stock Mentions - Seeking Alpha|
|View Insider Transactions for ALPMY - SECform4.com||View Insider Transactions for ALPMY - Insider Cow|
|View ALPMY Major Holdings Summary - CNBC||View Insider Disclosure for ALPMY - OTC Markets|
|View Insider Transactions for ALPMY - Yahoo! Finance||View Institutional Holdings for ALPMY - NASDAQ|
|View ALPMY Stock Insight & Charts - FinViz.com||View ALPMY Investment Charts - StockCharts.com|
|View ALPMY Stock Overview & Charts - BarChart||View ALPMY User Generated Charts - Trading View|
Astellas Acquires Universal Cells, Inc.
Posted on Tuesday February 13, 2018
TOKYO, Feb. 13, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Universal Cells, Inc. (CEO: Claudia Mitchell, "Universal Cells") today announced that Astellas has acquired Universal Cells. Astellas will gain Universal Cells' proprietary Universal Donor Cell technology to create cell therapy products that do not require Human Leukocyte Antigen (HLA) matching, potentially overcoming a huge treatment challenge by reducing the risk of rejection.
Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer
Posted on Monday February 05, 2018
TOKYO and NEW YORK , Feb. 5, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503), President and CEO: Yoshihiko Hatanaka , "Astellas," and Pfizer Inc. (NYSE: PFE) announced today results from ...
Astellas to Present New Oncology Data at the 2018 ASCO Genitourinary Cancers (GU) Symposium
Posted on Monday January 29, 2018
- A total of 10 abstracts and one trial in progress (TIP) across various cancers to be presented during oral and poster sessions - TOKYO , Jan. 29, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, ...
Astellas Completes Acquisition of Mitobridge, Inc.
Posted on Tuesday January 23, 2018
TOKYO, Jan. 23, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas" ) today announced that it has completed the acquisition of Mitobridge, Inc. ("Mitobridge"), and Mitobridge has become a wholly owned subsidiary of Astellas as of January 23, 2018 (U.S. Eastern Time). By exercising the option right to acquire Mitobridge, Astellas paid $225 million1 to acquire 100% of the equity in Mitobridge. In addition, Mitobridge shareholders will be eligible for additional payments from Astellas that total up to $225 million2 depending on the progress of various programs in clinical development.